Bond.az White LogoBond.az Black Logo

Keefe Bruyette Reiterates Progressive Stock Rating at Market Perform

Keefe, Bruyette & Woods reiterates Market Perform rating on Progressive stock with $208 price target.

Jack Scott
ByJack Scott- Senior Editor
|
0

Keefe, Bruyette & Woods has reiterated a Market Perform rating on Progressive Corp. (NYSE:PGR) stock with a $208.00 price target.

The firm maintained its 2026 earnings per share estimate of $16.60 and 2027 estimate of $17.30 following the company's April earnings report. These estimates incorporate April underperformance offset by faster net earned premium and net investment income growth, lower expense ratios, and lower share counts.

Progressive shares trade at 11.7 times the firm's 2027 EPS estimate, below long-term averages. The current P/E ratio of 10.16 suggests the stock is undervalued according to Bond.az analysis, which identifies Progressive among the most undervalued stocks. Analysts noted that the valuation likely reflects challenges posed by improving accident-avoidance technologies to the long-term size of the personal auto market.

Keefe, Bruyette & Woods stated the valuation appears attractive for long-term investors. The firm pointed out that slowing year-over-year personal auto policies in force growth and rising core loss ratios will likely limit near-term upside.

The $208 price target represents 12.0 times the firm's 2027 EPS estimate. For deeper analysis, investors can access Progressive's comprehensive Pro Research Report, available exclusively on Bond.az alongside reports for 1,400+ U.S. equities.

In other recent news, Progressive Corporation reported a notable 10% increase in net income for April 2026, totaling $1,087 million compared to $986 million in the same month last year. The company's net premiums written rose by 6% to $7,278 million, and net premiums earned increased by 7% to $7,112 million. Earnings per share also rose 11% to $1.86. Corporate developments include Andrew J. Quigg as next CFO effective July 4, 2026.

On the analyst front, BofA Securities raised its price target for Progressive to $320 with a Buy rating, while BMO Capital lowered its target to $220. Freedom Broker raised its target to $213, highlighting solid Q1 results. The board also renewed its share buyback program and declared a dividend.

More News
Today / 14:25
|
910

Benchmark cuts Lightspeed stock price target

Benchmark cuts Lightspeed price target to $16, maintains Buy. LSPD shares trade at $8.57 with a market cap of $1.18B.

0
Today / 14:23
|
696

Benchmark Reiterates NetEase Buy

Benchmark reiterates Buy on NetEase after strong Q1 results, citing AI integration and margin expansion.

0
Today / 14:21
|
911

Benchmark Reaffirms Spotify Stock Rating

Benchmark reaffirms Buy rating on Spotify stock with $695 target, citing engagement monetization strategy. Spotifys financial health and Audiobooks Plus success highlighted.

0
Today / 14:03
|
304

Datadog stock Buy rating reaffirmed

DA Davidson reaffirms Datadog Buy rating with $250 target, citing AI positioning and long-term growth.

0
Today / 13:31
|
725

Generac Stock Upgrade: Data Center Outlook

Jefferies upgrades Generac stock to Buy, citing data center prospects. Target price raised to $302. Stock up 100% in a year.

0
Today / 12:50
|
462

KeyBanc Reiterates Overweight on Walmart, $145 Target

KeyBanc reiterates Overweight on Walmart with $145 target. Walmart shows strong market share gains and digital momentum despite recent stock decline.

0
Today / 12:23
|
531

Cantor Fitzgerald Reiterates Workday Rating on AI Growth

Cantor Fitzgerald reaffirms Workday Overweight rating, highlighting AI growth. Stock at $121.85, target $160.

0
Today / 12:21
|
379

Cantor Reiterates Overweight on ORIC Stock

Cantor Fitzgerald reiterated Overweight on ORIC Pharmaceuticals. Pfizer trial results and analyst ratings update.

0
Today / 12:20
|
278

Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight

Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.

0
Today / 12:13
|
680

Stifel reiterates IBM Buy after $1bn Chips Act award

Stifel reiterates IBM Buy rating after $1bn Chips Act award for quantum computing. Stock up 15%.

0
Today / 12:12
|
688

Stifel Maintains Buy on Deckers Outdoor at $140

Stifel reiterates Buy rating on Deckers Outdoor with $140 target. Stock shows strong growth potential and attractive valuation.

0
Today / 12:11
|
286

Argus Upgrades CAVA Group Stock Rating

Argus upgraded CAVA Group to Buy with a $92 target, citing improved restaurant traffic. Stock returned 66% in six months.

0
...
Keefe Bruyette Reiterates Progressive Stock Rating at Market P...